By integrating DDT inhibition with biomarkers like homologous recombination deficiency and tumor mutational burden, this work can drive synthetic lethality, sensitize tumors to genotoxic agents, suppress treatment-induced mutagenesis, and potentially enhance responses to immunotherapy.
Audesh Bhat, G. Lahane, R. Pandita et al.· Trends in Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.